Excerpt: "...leronlimab)44,45 are CCR5 antagonists that inhibit HIV-1 virus from entering the T-cells.43 MRV binds to CCR5 and acts as an allosteric inverse agonist, locking CCR5 in an inactive conformation.42 However, recent research has focused more on cancer, as similarly to CCL5, CCR5 is overexpressed in many types of cancers, including breast28,33,34,46, prostate32 and in particular glioblastoma.47,48 Both maraviroc49 and leronlimab46 have been shown to potently block cancer metastasis in murine xenografts.